Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Risperidone + clozapine effective in chronic schizophrenia

Nov. 8, 1996

New treatment option for schizophrenia approved in Canada

Nov. 8, 1996

Scotia schizophrenia project develops rapidly

Nov. 8, 1996

5-HT1A receptor agonists from Sankyo

Nov. 8, 1996

Yoshitomi describes compounds for anxiety and epilepsy

Nov. 8, 1996

Migraine-related gene discovered by Dutch researchers

Nov. 8, 1996

Focus on present and future migraine therapy

Nov. 8, 1996

Menarini receives U.S. patent coverage for single-isomer analgesic

Nov. 8, 1996

Lilly reports 5-HT1F agonists for migraine

Nov. 8, 1996

Novel tachykinin antagonists from Glaxo Wellcome

Nov. 8, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.